Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Sulanda (surufatinib)
i
Other names:
HMPL-012, HMPL012, HMPL 012
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(7)
News
Trials
Company:
Hutchmed
Drug class:
VEGFR inhibitor, VEGFR-2 inhibitor, CSF-1R inhibitor, FGFR1 inhibitor, VEGFR-1 inhibitor, VEGFR-3 inhibitor
Related drugs:
‹
sunitinib (139)
lenvatinib (90)
axitinib (34)
fruquintinib (24)
cediranib (9)
TKI258 (9)
MGCD265 (4)
E 3810 (4)
OMP-305B83 (3)
ABT-869 (2)
chiauranib (1)
DC101 (1)
vorolanib (1)
KD019 (1)
BMS690514 (0)
CVX-241 (0)
ESK981 (0)
adAptVEGF-C adenoviral vector (0)
SU 14813 (0)
SYHA1813 (0)
VEGFR1-1084 (0)
ABT-165 (0)
IMC-18F1 (0)
ABT348 (0)
PI-88 (0)
SU5416 (0)
GS 6624 (0)
BAY 57- 9352 (0)
RG7221 (0)
PTK787 (0)
rivoceranib (82)
ramucirumab (59)
RAF265 (7)
SU5614 (6)
tivozanib (3)
GSK1363089 (2)
KC1036 (1)
OSI-930 (1)
BMS-582664 (1)
E7050 (1)
pegdinetanib (0)
BTG-002814 (0)
C019199 (0)
JI-101 (0)
JY025 (0)
firsekibart (0)
MG-D-1509 (0)
MSB0254 (0)
R1530 (0)
VEGFR2-169 (0)
VXM01 (0)
DCC-2701 (0)
gentuximab (0)
TTAC-0001 (0)
TSU-68 (0)
AK109 (0)
SYHA1817 (0)
NCE 401 (0)
ASA404 (0)
avapritinib (13)
TPX-0022 (8)
pexidartinib (6)
HX301 (2)
OPN-7486 (1)
BMS-986227 (1)
ABSK021 (1)
AMB-05X (0)
LY3022855 (0)
NMS-088 (0)
axatilimab-csfr (0)
vimseltinib (0)
Q702 (0)
3D185 (0)
BLZ-945 (0)
Max-40279 (2)
TT-00434 (1)
HMPL-453 (1)
ASP5878 (0)
FP-1039 (0)
LY2874455 (0)
OM-RCA-01 (0)
S-49076 (0)
SKI-G-801 (0)
plitidepsin (0)
EVT801 (0)
JNJ-26483327 (0)
SAR131675 (0)
sunitinib (139)
lenvatinib (90)
axitinib (34)
fruquintinib (24)
cediranib (9)
TKI258 (9)
MGCD265 (4)
E 3810 (4)
OMP-305B83 (3)
ABT-869 (2)
chiauranib (1)
DC101 (1)
vorolanib (1)
KD019 (1)
BMS690514 (0)
CVX-241 (0)
ESK981 (0)
adAptVEGF-C adenoviral vector (0)
SU 14813 (0)
SYHA1813 (0)
VEGFR1-1084 (0)
ABT-165 (0)
IMC-18F1 (0)
ABT348 (0)
PI-88 (0)
SU5416 (0)
GS 6624 (0)
BAY 57- 9352 (0)
RG7221 (0)
PTK787 (0)
rivoceranib (82)
ramucirumab (59)
RAF265 (7)
SU5614 (6)
tivozanib (3)
GSK1363089 (2)
KC1036 (1)
OSI-930 (1)
BMS-582664 (1)
E7050 (1)
pegdinetanib (0)
BTG-002814 (0)
C019199 (0)
JI-101 (0)
JY025 (0)
firsekibart (0)
MG-D-1509 (0)
MSB0254 (0)
R1530 (0)
VEGFR2-169 (0)
VXM01 (0)
DCC-2701 (0)
gentuximab (0)
TTAC-0001 (0)
TSU-68 (0)
AK109 (0)
SYHA1817 (0)
NCE 401 (0)
ASA404 (0)
avapritinib (13)
TPX-0022 (8)
pexidartinib (6)
HX301 (2)
OPN-7486 (1)
BMS-986227 (1)
ABSK021 (1)
AMB-05X (0)
LY3022855 (0)
NMS-088 (0)
axatilimab-csfr (0)
vimseltinib (0)
Q702 (0)
3D185 (0)
BLZ-945 (0)
Max-40279 (2)
TT-00434 (1)
HMPL-453 (1)
ASP5878 (0)
FP-1039 (0)
LY2874455 (0)
OM-RCA-01 (0)
S-49076 (0)
SKI-G-801 (0)
plitidepsin (0)
EVT801 (0)
JNJ-26483327 (0)
SAR131675 (0)
›
Associations
(7)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Neuroendocrine Tumor
No biomarker
Neuroendocrine Tumor
surufatinib
Sensitive: A1 - Approval
surufatinib
Sensitive
:
A1
surufatinib
Sensitive: A1 - Approval
surufatinib
Sensitive
:
A1
PD-L1 underexpression
Gastric Adenocarcinoma
PD-L1 underexpression
Gastric Adenocarcinoma
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
PD-L1 underexpression
Esophageal Squamous Cell Carcinoma
PD-L1 underexpression
Esophageal Squamous Cell Carcinoma
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
PD-L1 expression
Neuroendocrine Tumor
PD-L1 expression
Neuroendocrine Tumor
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
PD-L1 expression
Esophageal Squamous Cell Carcinoma
PD-L1 expression
Esophageal Squamous Cell Carcinoma
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
PD-L1 expression
Gastroesophageal Junction Adenocarcinoma
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
PD-L1 expression
Gastric Cancer
PD-L1 expression
Gastric Cancer
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
toripalimab-tpzi + surufatinib
Sensitive: C3 – Early Trials
toripalimab-tpzi + surufatinib
Sensitive
:
C3
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.